Research Briefs

Medicine · Surgery

Bariatric Surgery and Outcomes

Log in to follow
Abstract editorial illustration accompanying the article: Review finds no clear increase in digestive-tract tumors with SGLT2 drugs
Health & Medicine
High evidenceReview

Review finds no clear increase in digestive-tract tumors with SGLT2 drugs

Researchers combined results from 49 randomized controlled trials involving 49,054 people with type 2 diabetes to examine whether SGLT2 inhibitors were linked with gastrointestinal neoplasms, meaning tumors or abnormal growths in the digestive system. The analysis found no statistically significant association with gastrointestinal neoplasms overall or with the specific sites studied. However, about half of the trials lasted one year or less, so the analysis provides limited information about long-term risk.

·30 views
Abstract editorial illustration accompanying the article: Trial reports weight loss with a daily oral GLP-1 medicine over 16 weeks
Health & Medicine
Moderate evidenceHuman study

Trial reports weight loss with a daily oral GLP-1 medicine over 16 weeks

In a randomized, placebo-controlled phase II trial of 250 adults with overweight or obesity in China, the oral GLP-1 receptor agonist VCT220 was associated with greater average weight loss over 16 weeks than placebo. The study also reported changes in HbA1c, fasting insulin, and blood pressure, while gastrointestinal side effects were common but usually mild to moderate. Longer-term effects and safety remain uncertain.

·28 views
Abstract editorial illustration accompanying the article: Review examines why low blood sugar can happen after stomach surgery for gastric cancer
Health & Medicine
Moderate evidenceReview

Review examines why low blood sugar can happen after stomach surgery for gastric cancer

This narrative review discusses postgastrectomy hypoglycemia (PGH), a low-blood-sugar complication that can occur after stomach surgery for gastric cancer. It summarizes possible mechanisms, including hormone-related effects, and describes how continuous glucose monitoring may reveal symptoms that are not always obvious. The review emphasizes that medication evidence specifically for PGH is limited, so overall conclusions are cautious.

·30 views